CN111892513A - Benzoic acid hapten, benzoic acid complete antigen, preparation method thereof and reagent strip - Google Patents
Benzoic acid hapten, benzoic acid complete antigen, preparation method thereof and reagent strip Download PDFInfo
- Publication number
- CN111892513A CN111892513A CN202010468006.7A CN202010468006A CN111892513A CN 111892513 A CN111892513 A CN 111892513A CN 202010468006 A CN202010468006 A CN 202010468006A CN 111892513 A CN111892513 A CN 111892513A
- Authority
- CN
- China
- Prior art keywords
- benzoic acid
- antibody
- pad
- gold
- complete antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title claims abstract description 244
- 239000005711 Benzoic acid Substances 0.000 title claims abstract description 126
- 235000010233 benzoic acid Nutrition 0.000 title claims abstract description 121
- 239000000427 antigen Substances 0.000 title claims abstract description 46
- 102000036639 antigens Human genes 0.000 title claims abstract description 46
- 108091007433 antigens Proteins 0.000 title claims abstract description 46
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 72
- 238000006243 chemical reaction Methods 0.000 claims description 43
- 239000000243 solution Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 17
- 102000014914 Carrier Proteins Human genes 0.000 claims description 15
- 108010078791 Carrier Proteins Proteins 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000003908 quality control method Methods 0.000 claims description 14
- 239000010931 gold Substances 0.000 claims description 12
- 229910052737 gold Inorganic materials 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 108010074605 gamma-Globulins Proteins 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 235000010288 sodium nitrite Nutrition 0.000 claims description 3
- 239000010414 supernatant solution Substances 0.000 claims description 3
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 102000009843 Thyroglobulin Human genes 0.000 claims description 2
- 108010034949 Thyroglobulin Proteins 0.000 claims description 2
- 238000009739 binding Methods 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 2
- 229960002175 thyroglobulin Drugs 0.000 claims description 2
- 238000003317 immunochromatography Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 abstract description 6
- 230000000890 antigenic effect Effects 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 238000002649 immunization Methods 0.000 description 11
- 230000003053 immunization Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- -1 small molecule compounds Chemical class 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004454 trace mineral analysis Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/20—Diazonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nanotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a benzoic acid hapten, a benzoic acid complete antigen, a preparation method thereof and a reagent strip. In the benzoic acid complete antigen, the antigenic determinant of the benzoic acid molecule can be fully exposed and has complete spatial conformation, so that the benzoic acid complete antigen provided by the invention has better immunogenicity and can be used for immunoassay.
Description
Technical Field
The invention relates to the field of biomedicine, in particular to a benzoic acid hapten, a benzoic acid complete antigen, a preparation method thereof and a reagent strip.
Background
The immunoassay is a trace analysis method based on specific recognition and reversible binding reaction between an antigen and an antibody, and is suitable for detection of macromolecular compounds (such as proteins, nucleic acids and bacteria) and measurement of small molecular compounds (such as hormones and drugs). The key to establishing an immunoassay method for small molecule compounds is the ability to prepare antibodies with high affinity and high selectivity for small molecule compounds. Most small molecule compounds have molecular weight less than 1000, and are not immunogenic, i.e., lack of T cell epitope and cannot directly induce animal body to produce specific antibody. However, the small molecule compound can be combined with the macromolecular carrier by a proper chemical modification method to generate a small molecule compound-macromolecular carrier coupling substance, namely a complete antigen, which can indirectly induce the proliferation and differentiation of B cells by means of T cell epitopes to generate specific antibodies.
Benzoic acid (MLT) is a small molecule substance with chemical name of N-acetyl-5-methoxy tryptamine, molecular weight of 232.28D only, and is not immunogenic, and is used for immunization, and must be combined with a protein macromolecular carrier to form a complete antigen of benzoic acid-protein carrier coupling. However, the preparation of benzoic acid-protein carrier conjugated complete antigen cannot affect the steric conformation of benzoic acid, and the effectiveness of benzoic acid antigenic determinants (such as 5-methoxy, N-alkyl side chains) needs to be maintained to obtain high-titer and high-specificity benzoic acid antibody. Therefore, how to prepare complete antigens with good immunogenicity is a difficult point to establish an immunoassay method for measuring benzoic acid.
Disclosure of Invention
The invention provides a benzoic acid hapten and aims to solve the problems.
According to a first aspect of embodiments herein, there is provided a benzoic acid hapten of the formula:
according to a second aspect of the embodiments of the present application, there is provided a method for preparing a benzoic acid complete antigen, comprising the steps of:
providing benzoic acid;
dissolving the benzoic acid in a proper amount of distilled water, adjusting the pH value to 1-2, and stirring in an ice bath at the temperature of 4 ℃ for 10 minutes to obtain a reaction solution;
slowly adding the precooled 1M sodium nitrite solution into the reaction solution, and continuing to react for 30 minutes at the temperature of 4 ℃ to obtain the benzoic acid hapten as claimed in claim 1.
According to a third aspect of the embodiments herein, there is provided a benzoic acid complete antigen having the formula:
in the structural formula, R is carrier protein, n is 5～20, is a natural number.
According to a fourth aspect of the embodiments of the present application, there is provided a method for preparing a benzoic acid complete antigen, comprising the steps of:
preserving the benzoic acid hapten as defined in claim 1 at 0-4 ℃ to obtain a first reaction solution;
preparing a phosphate buffer solution of the carrier protein;
dropwise adding the first reaction solution into the phosphate buffer solution of the carrier protein, and stirring at 0-4 ℃ to obtain a mixed solution containing a benzoic acid complete antigen;
and dialyzing the mixed solution, and centrifuging to obtain a supernatant solution containing the benzoic acid complete antigen.
According to a fourth aspect of the embodiments of the present application, there is provided a colloidal gold immunochromatographic reagent strip for detecting benzoic acid, comprising a back plate, a sample pad, a gold-labeled pad, a reaction pad, and a water absorption pad, wherein the sample pad, the gold-labeled pad, the reaction pad, and the water absorption pad are sequentially disposed on the back plate; the reaction pad is provided with a detection line and a quality control line, the detection line is coated with a benzoic acid complete antigen, the quality control line is coated with an antibody of an anti-benzoic acid antibody gold-labeled compound, the gold-labeled pad is sprayed with the benzoic acid antibody gold-labeled compound, and the structural formula of the benzoic acid complete antigen is shown in the specification
The technical scheme provided by the embodiment of the application can have the following beneficial effects: the benzoic acid complete antigen provided by the invention comprises benzoic acid molecules and carrier protein, wherein the benzoic acid molecules and the carrier protein are connected through a connecting arm, and in the benzoic acid complete antigen, antigenic determinants of the benzoic acid molecules can be fully exposed and have complete spatial conformation, so that the benzoic acid complete antigen provided by the invention has better immunogenicity.
The colloidal gold immunochromatographic reagent strip for detecting benzoic acid provided by the invention can be used for immunoassay of benzoic acid, the detection sensitivity is greatly improved, and all positive samples of benzoic acid can be rapidly screened out through the colloidal gold kit.
The colloidal gold immunochromatographic reagent strip for detecting benzoic acid provided by the invention has short detection time; no special instrument is needed; the operation is simple, the operator does not need training, and the detection cost is low. The test paper is conventional test paper, the antibody can be prepared according to the method provided by the invention, large-scale production can be carried out, and the production cost is low.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on the drawings without creative efforts.
FIG. 1 is a schematic structural diagram of a colloidal gold immunochromatographic reagent strip for detecting benzoic acid according to an embodiment of the present invention.
Description of reference numerals:
10. a back plate; 20. a sample pad; 30. a gold label pad; 40. a reaction pad; 41. detecting lines; 42. a quality control line; 50. An absorbent pad.
Detailed Description
The technical solutions in the embodiments of the present invention will be described clearly and completely with reference to the accompanying drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without any inventive step, are within the scope of the present invention.
It is also to be understood that the terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in this specification and the appended claims, the singular forms "a", "an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
The reagents and biomaterials in the examples described below are commercially available without specific reference.
The invention discloses a benzoic acid hapten and a preparation method thereof, wherein the structural formula of the benzoic acid hapten is
The preparation method of the benzoic acid hapten comprises the steps of S101-S103.
S101, providing benzoic acid. Specifically, the structural formula of the benzoic acid is shown as
S102, dissolving the benzoic acid in a proper amount of distilled water, adjusting the pH value to 1-2, and stirring for 10 minutes at a low temperature of 4 ℃ in an ice bath to obtain a reaction solution.
S103, slowly adding the precooled 1M sodium nitrite solution into the reaction liquid A, wherein the color is immediately changed into light yellow, and continuously reacting for 30 minutes at the temperature of 4 ℃ to obtain the benzoic acid hapten.
In an alternative embodiment, the present invention discloses a benzoic acid complete antigen having the formula:
in the structural formula, R is carrier protein, and n is a natural number of 5-20.
The invention also discloses a preparation method of the benzoic acid complete antigen, which comprises the steps S201-S204.
S201, preserving the benzoic acid hapten at 0-4 ℃ for later use to obtain a first reaction solution.
S202, preparing a phosphate buffer solution of carrier protein.
In particular, the molar concentration of the carrier protein is 1X 10-3mol/L, and the molar concentration of the phosphate is 0.01 mol/L.
S203, dropwise adding the first reaction solution into the phosphate buffer solution of the carrier protein, and stirring at 0-4 ℃ for reaction to obtain a mixed solution containing the benzoic acid complete antigen.
S204, dialyzing the mixed solution containing the benzoic acid complete antigen, and centrifuging to obtain a supernatant solution containing the benzoic acid complete antigen.
The structural formula of the benzoic acid complete antigen (MLT-BSA conjugate) is shown in the specification
R is carrier protein, and n is natural number of 5-20.
In an alternative embodiment, the carrier protein is any one of globulin, bovine serum albumin, chicken ovalbumin, keyhole limpet hemocyanin, rabbit serum albumin, human serum albumin, thyroglobulin, fibrinogen, rabbit gamma globulin, and chicken gamma globulin.
Referring to fig. 1, the present invention also discloses a colloidal gold immunochromatographic reagent strip for detecting benzoic acid, which comprises a back plate 10, a sample pad 20, a gold label pad 30, a reaction pad 40 and a water absorption pad 50. Wherein sample pad 20, gold mark pad 30, reaction pad 40 and absorb water pad 50 set gradually on backplate 10, and sample pad 20 and absorb water pad 50 set up respectively in two tip of backplate 10, and reaction pad 40 sets up in the middle part of backplate 10, and the lower surface that is close to the tip of reaction pad 40 of gold mark pad 30 is laminated with the upper surface of reaction pad 40, and the upper surface that is close to the tip of sample pad 20 on the gold mark pad 30 is laminated with the lower surface of sample pad 20. The upper surface of the reaction pad 40 far away from the gold-labeled pad 30 is attached to the upper surface of the water absorption pad 50, so that the liquid to be detected can fully overflow to the reaction pad 40 and is finally absorbed by the water absorption pad 50. The reaction pad 40 is provided with a detection line 41 and a quality control line 42 which are arranged in parallel at intervals, the detection line 41 is coated with a benzoic acid complete antigen, the quality control line 42 is coated with an antibody of an anti-benzoic acid antibody gold-labeled compound, the gold-labeled pad is sprayed with the benzoic acid antibody gold-labeled compound, wherein the structural formula of the benzoic acid complete antigen is shown as
The invention also provides a preparation method of the colloidal gold immunochromatographic reagent strip for detecting benzoic acid, which comprises the steps S301-S303.
S301, preparing a benzoic acid antibody, colloidal gold and a gold-labeled pad.
Specifically, the benzoic acid antibody is prepared by taking a benzoic acid complete antigen as an immunogen and adopting a conventional method. The colloidal gold is prepared by adopting a trisodium citrate reduction method.
The preparation method of the gold-labeled pad comprises the following steps of dipping the glass fiber by the treatment solution, drying, spraying the benzoic acid antibody gold-labeled compound on the pretreated glass fiber in an amount of 0.5-4 mu l/cm, drying at the ambient temperature of 25-30 ℃ to obtain the gold-labeled pad, and placing the gold-labeled pad in the environment of 2-8 ℃ for later use. When the benzoic acid antibody gold-labeled compound is prepared, the PH value of colloidal gold is adjusted to 7.0-9.0, under the stirring condition, the benzoic acid antibody is slowly added according to the dosage of adding 4-25 mu g of protein into each milliliter of colloidal gold solution, the mixture is kept stand for 10-30 min, bovine serum albumin BSA is added to the mixture until the final concentration is 0.5-5%, the mixture is kept stand for 10-30 min, the centrifugation is carried out, the supernatant is discarded, the precipitate is washed for 2-3 times by using the washing solution, the precipitate is resuspended by using the resuspension liquid with one tenth of the initial volume at the end, and the precipitate is kept at 4 ℃ for later use
And S302, setting a detection line and a quality control line.
Specifically, the detection line is set by taking a benzoic acid resistant complete antigen, diluting the benzoic acid resistant complete antigen with a coating buffer solution until the concentration of the benzoic acid resistant complete antigen is 1.0-1.5 mg/mL, taking a reaction pad, and scratching the benzoic acid resistant complete antigen on the reaction pad by using a film scratching instrument with the dosage of 1-10 mu l/cm to form the detection line.
The setting of the quality control line comprises diluting the goat anti-mouse antibody with a coating buffer solution until the concentration is 0.8-1.5 mg/mL, then scratching the goat anti-mouse antibody on the reaction pad with the dosage of 1-10 mul/cm to form the quality control line, and then placing the reaction pad at 37 ℃ for drying for later use.
S303, assembling a colloidal gold immunochromatographic reagent strip for detecting benzoic acid.
Specifically, get backplate, sample pad, absorb water the pad, the gold mark pad after handling and the reaction pad after handling and assemble, obtain the colloidal gold immunochromatographic assay reagent strip that detects benzoic acid, wherein sample pad, gold mark pad, reaction pad and absorb water the pad set gradually in on the backplate, sample pad and absorption water pad set up respectively in two tip of backplate, and the reaction pad sets up in the middle part of backplate, and the lower surface that is close to the tip of reaction pad of gold mark pad is laminated with the upper surface of reaction pad, and the upper surface that is close to the tip of sample pad on the gold mark pad is laminated with the lower surface of sample pad. The upper surface of one end of the reaction pad, which is far away from the gold mark pad, is attached to the upper surface of the water absorption pad, so that the liquid to be detected is fully overflowed onto the reaction pad through the structure and is finally absorbed by the water absorption pad. The reaction pad is provided with a detection line and a quality control line which are arranged in parallel at intervals, the detection line is coated with a benzoic acid complete antigen, the quality control line is coated with an antibody of an anti-benzoic acid antibody gold-labeled compound, and the gold-labeled pad is sprayed with the benzoic acid antibody gold-labeled compound.
In some alternative embodiments, the reagent strip may be installed in a casing, the reaction pad is exposed to allow a user to observe the reaction of the reaction pad from the outside, and the casing corresponding to the sample pad is opened to allow the user to insert the sample onto the sample pad through the opening.
In an alternative embodiment, the benzoic acid antibody gold-labeled complex comprises benzoic acid antibody and colloidal gold nanoparticles, and the benzoic acid antibody is monoclonal antibody or polyclonal antibody. The benzoic acid antibody gold-labeled compound is formed by combining benzoic acid antibody and colloidal gold nanoparticles in an electrostatic manner. The antibody of the anti-benzoic acid antibody gold-labeled compound coated on the quality control line is a monoclonal antibody or a polyclonal antibody. The polyclonal antibody is any one of a mouse source, a horse source, a sheep source, a rabbit source and a guinea pig source, and the monoclonal antibody is a mouse source or a rabbit source.
In an alternative embodiment, the benzoic acid antibody is a monoclonal antibody of benzoic acid antibody, and the preparation method comprises steps S401-S404.
S401, animal immunization.
The conjugate MLT-BSA is used as an immunizing antigen to immunize Balb/c mice, and the weight is 100 mu g/kg. Mixing immunogen and equivalent Freund complete adjuvant to prepare emulsifier during first immunization, performing subcutaneous multipoint injection on neck and back, taking the same dose of immunogen and the equivalent Freund incomplete adjuvant at intervals of 2 weeks, mixing and emulsifying, continuing three-immunization, performing the same dose of method and two-immunization, taking blood from tail after one week of three-immunization to detect serum titer and inhibition, performing abdominal cavity impact immunization once when the requirement is met, and taking splenocytes after 3 days.
S401, cell fusion and cloning.
Taking splenocytes of the immune Balb/c mice, and carrying out the following steps: 1 ratio was fused with SP2/0 myeloma cells, and positive wells were screened by measuring cell supernatants using an indirect competitive ELISA. Cloning the positive hole by using a limiting dilution method until obtaining the hybridoma cell strain which stably secretes the monoclonal antibody.
S401, freezing and restoring cells.
Preparing hybridoma cells in logarithmic growth phase into 5 xl 06 cell suspension with freezing medium, subpackaging in freezing tube, and storing in liquid nitrogen for a long time. Taking out the frozen tube during recovery, immediately putting the tube into a water bath at 37 ℃ for fast melting, centrifuging to remove frozen liquid, and transferring the tube into a culture bottle for culture.
S401, preparing and purifying the monoclonal antibody.
By adopting an in vivo induction method, 0.5ml of Freund's incomplete adjuvant is injected into the abdominal cavity of a Balb/c mouse aged for 8 weeks, 5 xl 06 hybridoma cells are injected into the abdominal cavity after 7 days, and ascites is collected after 7 days. Purifying ascites with affinity chromatographic column, measuring protein concentration with ultraviolet spectrophotometer, and storing at-20 deg.c. The titer of the purified antibody is measured by an ELISA method to be 1:128000, and the result shows that the purified antibody has higher specificity and sensitivity to the benzoic acid.
In an alternative embodiment, the benzoic acid antibody is a polyclonal benzoic acid antibody, and the preparation method comprises steps S501-S502.
S501, animal immunization.
The conjugate MLT-BSA is used as an immunizing antigen to immunize Balb/c mice of 8 weeks old with 1mg/kg body weight. Mixing the immunogen and an equal amount of Freund's complete adjuvant to prepare an emulsifier during first immunization, performing subcutaneous multipoint injection on the neck and the back, taking the same dose of immunogen and an equal amount of Freund's incomplete adjuvant at intervals of 2 weeks, mixing and emulsifying, and performing booster immunization once for 5 times in total.
S502, collection of antiserum and purification of polyclonal antibody.
Blood is collected 7 days after the last immunization, the titer of the antibody of the serum is measured, the abdominal artery is used for collecting the whole blood and collecting the serum, the purified polyclonal antibody is obtained by the separation of an affinity chromatography column, the titer of the purified antibody is measured by an ELISA method at the ratio of 1:10000, and the purified antibody shows higher specificity and sensitivity to the benzoic acid.
In an alternative embodiment, the preparation of the colloidal gold specifically includes steps S601 to S602.
S601, dissolving 1g of chloroauric acid (HauCL4) in 100g of ultrapure water to prepare a 1% chloroauric acid solution 4C, and standing for later use;
s602, dissolving 1g of trisodium citrate dihydrate into 100g of ultrapure water to prepare a 1% trisodium citrate dihydrate solution 4C, and placing for later use;
s603, adding 100ml of ultrapure water into a clean triangular flask, placing the flask on a heated magnetic stirrer, stirring and heating the flask to boiling, then adding 1ml of 1% chloroauric acid, quickly adding 1.7ml of 1% trisodium citrate dihydrate solution after the flask is boiled, continuing to heat and stir for 15 minutes after the color is changed into wine red, and then stopping heating and stirring. Naturally cooling the prepared colloidal gold for later use; the prepared colloidal gold has the particle size of 25nm and the maximum absorption peak of 521 nm.
In an alternative embodiment, the specific preparation method of the benzoic acid antibody gold-labeled complex comprises steps S701-S702.
S701, searching the optimal protein concentration marked by the colloidal gold.
Taking 8 polystyrene micro-reaction tubes, adding 30ul of triple distilled water into each hole, adding 30ul of the benzoic acid antibody prepared in the fourth embodiment into the first hole, diluting the mixture in a multiple ratio to the last hole, adding 125ul of Ph8.0 colloidal gold solution into each hole, standing the mixture at room temperature for 15min, adding 125ul of 10% NaCl solution into each hole, observing the change of each hole, and taking the hole without color change as the minimum protein concentration (5ug/ml-10 ug/ml).
S702, adjusting the pH value of colloidal gold to 8.0, slowly adding the benzoic acid antibody according to the dosage of adding 4-25 mu g of protein into each milliliter of colloidal gold solution under the stirring condition, standing for 30min, then adding bovine serum albumin BSA to the final concentration of 1%, standing for 30min, centrifuging for 30min at 4 ℃ under 12000, discarding the supernatant, washing the precipitate for 2 times by using a washing solution, re-suspending the precipitate by using a tenth of the initial volume of a resuspension solution at the last time to obtain a benzoic acid antibody gold-labeled compound, and standing for later use at 4 ℃.
The resuspension solution, namely the preservation solution, is borate, carbonate, phosphate, Tris-HCl or Tris-phosphate, acetate, barbital and the like containing 0.2-1% of macromolecular protein, the macromolecular protein can be bovine serum albumin, PEG20000, casein and the like, and the buffer solution is preferably a phosphate buffer solution, more preferably 0.5% BSA phosphate buffer solution with the pH value of 7.4.
In addition, the preparation method of the colloidal gold immunochromatographic reagent strip for detecting benzoic acid provided in this embodiment is only one of the ways of applying the benzoic acid complete antigen, the benzoic acid antibody gold-labeled complex, and the antibody against the benzoic acid antibody gold-labeled complex provided in the present invention. Other applications, particularly for immunoassay of benzoic acid, are considered to be within the scope of the embodiments of the present invention; in addition, the colloidal gold immunochromatographic reagent strip for detecting benzoic acid provided by the invention can be packaged, and comprises the following steps: and (3) assembling 1 part of cut test paper in a prepared test paper card, enabling the sample adding window to correspond to the sample pad of the test paper, and enabling the result display window to correspond to the detection area and the control area. And packaging the dried powder in an outer bag together with a bag of drying agent, a specification and a sample injector, and storing the packaged powder at 4-25 ℃ in a dark place.
The above description is only for the specific embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive various equivalent modifications or substitutions within the technical scope of the present invention, and these modifications or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (10)
1. A benzoic acid hapten having the formula:
2. a preparation method of a benzoic acid complete antigen is characterized by comprising the following steps:
providing benzoic acid;
dissolving the benzoic acid in a proper amount of distilled water, adjusting the pH value to 1-2, and stirring in an ice bath at the temperature of 4 ℃ for 10 minutes to obtain a reaction solution;
slowly adding the precooled 1M sodium nitrite solution into the reaction solution, and continuing to react for 30 minutes at the temperature of 4 ℃ to obtain the benzoic acid hapten as claimed in claim 1.
3. A benzoic acid complete antigen, characterized in that it has the structural formula:
in the structural formula, R is carrier protein, and n is a natural number of 5-20.
4. A preparation method of a benzoic acid complete antigen is characterized by comprising the following steps:
preserving the benzoic acid hapten as defined in claim 1 at 0-4 ℃ to obtain a first reaction solution;
preparing a phosphate buffer solution of the carrier protein;
dropwise adding the first reaction solution into the phosphate buffer solution of the carrier protein, and stirring at 0-4 ℃ to obtain a mixed solution containing a benzoic acid complete antigen;
and dialyzing the mixed solution, and centrifuging to obtain a supernatant solution containing the benzoic acid complete antigen.
5. The method of preparing a benzoic acid complete antigen as claimed in claim 4, wherein the carrier protein is any one of globulin, bovine serum albumin, chicken ovalbumin, keyhole limpet hemocyanin, rabbit serum albumin, human serum albumin, thyroglobulin, fibrinogen, rabbit gamma globulin and chicken gamma globulin.
6. The colloidal gold immunochromatographic reagent strip for detecting benzoic acid is characterized by comprising a back plate, a sample pad, a gold label pad, a reaction pad and a water absorption pad, wherein the sample pad, the gold label pad, the reaction pad and the water absorption pad are sequentially arranged on the back plate; the reaction pad is provided with a detection line and a quality control line, the detection line is coated with a benzoic acid complete antigen, the quality control line is coated with an antibody of an anti-benzoic acid antibody gold-labeled compound, the gold-labeled pad is sprayed with the benzoic acid antibody gold-labeled compound, and the structural formula of the benzoic acid complete antigen is shown in the specification
7. The colloidal gold immunochromatographic reagent strip for detecting benzoic acid according to claim 6, wherein the benzoic acid antibody gold-labeled complex comprises a benzoic acid antibody and colloidal gold nanoparticles, and the benzoic acid antibody is a monoclonal antibody or a polyclonal antibody.
8. The reagent strip for immunochromatography of benzoic acid detection according to claim 7, wherein the benzoic acid antibody-gold labeled complex is formed by electrostatically binding the benzoic acid antibody and the colloidal gold nanoparticles.
9. The colloidal gold immunochromatographic reagent strip for detecting benzoic acid according to claim 6, wherein the antibody of the benzoic acid antibody gold-labeled complex coated on the quality control line is a monoclonal antibody or a polyclonal antibody.
10. The colloidal gold immunochromatographic reagent strip for detecting benzoic acid according to claim 7 or 9, wherein the polyclonal antibody is any one of mouse, horse, sheep, rabbit and guinea pig, and the monoclonal antibody is mouse or rabbit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010468006.7A CN111892513A (en) | 2020-05-28 | 2020-05-28 | Benzoic acid hapten, benzoic acid complete antigen, preparation method thereof and reagent strip |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010468006.7A CN111892513A (en) | 2020-05-28 | 2020-05-28 | Benzoic acid hapten, benzoic acid complete antigen, preparation method thereof and reagent strip |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111892513A true CN111892513A (en) | 2020-11-06 |
Family
ID=73206888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010468006.7A Pending CN111892513A (en) | 2020-05-28 | 2020-05-28 | Benzoic acid hapten, benzoic acid complete antigen, preparation method thereof and reagent strip |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111892513A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113640523A (en) * | 2021-09-10 | 2021-11-12 | 河南农业大学 | Colloidal gold immunochromatographic test strip for detecting benzoic acid in liquid food |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103351433A (en) * | 2013-05-24 | 2013-10-16 | 华南农业大学 | Benzoic acid artificial antigen and antibody, and preparation methods and applications thereof |
| CN105277665A (en) * | 2014-07-24 | 2016-01-27 | 江苏维赛科技生物发展有限公司 | Test paper strip for rapidly detecting overstandard preservative benzoic acid |
-
2020
- 2020-05-28 CN CN202010468006.7A patent/CN111892513A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103351433A (en) * | 2013-05-24 | 2013-10-16 | 华南农业大学 | Benzoic acid artificial antigen and antibody, and preparation methods and applications thereof |
| CN105277665A (en) * | 2014-07-24 | 2016-01-27 | 江苏维赛科技生物发展有限公司 | Test paper strip for rapidly detecting overstandard preservative benzoic acid |
Non-Patent Citations (3)
| Title |
|---|
| 吴定等: ""食品中苯甲酸含量竞争ELISA测定"", 《中国卫生检验杂志》 * |
| 曾文亮等: ""苯甲酸免疫胶体金快速检测试纸条的研制"", 《食品工业科技》 * |
| 陈百科等: ""乳饮料中苯甲酸快速检测试剂盒的研制及应用"", 《中国乳品工业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113640523A (en) * | 2021-09-10 | 2021-11-12 | 河南农业大学 | Colloidal gold immunochromatographic test strip for detecting benzoic acid in liquid food |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104736567B (en) | The antibody and application thereof of Aripiprazole haptens | |
| WO2022183762A1 (en) | Anti-phenacetin monoclonal antibody hybridoma cell strain ad, and preparation method therefor and use thereof | |
| WO2014005298A1 (en) | Enzyme-linked immunosorbent assay kit for detecting dinitolmide and use thereof | |
| CN108912090B (en) | Test strip for rapidly detecting total amount of alternariol and alternariol monomethyl ether | |
| CN106918705B (en) | Test paper for detecting fenpropathrin and application thereof | |
| WO2005042579A1 (en) | Anti-sars virus antibody, hybridoma producing the antibody and immunoassay reagent using the antibody | |
| CN111892513A (en) | Benzoic acid hapten, benzoic acid complete antigen, preparation method thereof and reagent strip | |
| JP4174016B2 (en) | Immunochromatographic detection method and test kit for thylosins by competitive method | |
| CN111763658A (en) | Hybridoma cell strain secreting anti-dinitrotolamine monoclonal antibody and application thereof | |
| CN107003304A (en) | For Oxycodone and the conjugate of the determination method of Oxymorphone | |
| CN111220802B (en) | Clenbuterol hydrochloride small molecule hapten high sensitivity detection test paper based on nano antibody and preparation method thereof | |
| CN111072777B (en) | Anti mHIN2Protein antibody, application thereof and kit containing protein antibody | |
| EP0208953A1 (en) | Histamine derivatives, immunogen conjugates and antibodies raised thereto | |
| CN111961128A (en) | Amoxicillin complete antigen and preparation method thereof, and reagent strip and preparation method thereof | |
| CN111533665A (en) | Rimantadine hapten, rimantadine complete antigen, preparation method thereof and test strip | |
| CN107102132A (en) | Quantum dot fluorescence probe and preparation method thereof, immune chromatography test paper | |
| CN113030463A (en) | Test strip for detecting protein A and other impurities in vaccine and application thereof | |
| WO1993003365A1 (en) | Immunoassay, monoclonal antibody and hybridoma | |
| CN103163302B (en) | Oligopeptide antibody kit prepared by directional cross-coupling technology | |
| Culling et al. | The effect of various fixatives and trypsin digestion upon the staining of routine paraffin-embedded sections by the peroxidase-antiperoxidase and immunofluorescent technique | |
| CN112480167A (en) | Isocarbophos hapten, artificial antigen and antibody, and preparation method and application thereof | |
| CN105859885B (en) | Anti-human mycoplasma pneumoniae P30 protein antibody and immunochromatography kit applying same | |
| CN114181909B (en) | Hybridoma cell strain, monoclonal antibody thereof and kit | |
| CN110616194A (en) | Aconitine monoclonal antibody cell strain SJ and application thereof | |
| CN112724138B (en) | Cocaine hapten, artificial antigen, antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201106 |
|
| RJ01 | Rejection of invention patent application after publication |